CENTRE FOR DRUG SAFETY SCIENCE

Lead Research Organisation: University of Liverpool
Department Name: Unlisted

Abstract

It is estimated that adverse reactions to drugs constitute the 4th most common cause of death in the USA. In the UK, adverse drug reactions (ADRs) are a financial burden on the health services, a major cause of drug withdrawals for the pharmaceutical industry and a life-threatening experience for some patients. A recent survey indicated that 6.5% of hospital admissions were due to ADRs costing the Nation #466 million annually. With the increasing emphasis on polypharmacy and multidrug combination therapy, this situation is set to worsen. At the individual level, whilst many ADRs are relatively mild and self-limiting, in some cases ? in particular the allergic or hypersensitivity reactions ? they can result in permanent disability or fatality. Several recent high profile incidences of adverse drug reactions, for example the withdrawal of Vioxx (a COX2 inhibitor) because of heart attacks and the TGN1412 incident in Northwick Park in 6 healthy volunteers, have undermined confidence in existing preclinical testing procedures, and subsequent safety assessment in man. Despite this, our understanding of ADRs and the mechanisms underlying them are seriously deficient. ADRs are complex biological events which require broad-based expertise and meticulously conducted clinical studies to address. The Centre for Drug Safety Science will provide a unique infrastructure for studying the mechanisms of ADRs and will provide a focus for establishing the critical mass of expertise required to make a real impression on the incidence, prediction and management of such reactions, both within the health services and pharmaceutical industry. Our mission therefore is to create a world-class centre for the investigation of fundamental mechanisms by which adverse drug reactions which are important in our clinics and hospitals, with the overall aim of preventing such reactions through (a) better design of drugs, (b) identifying the factors by which ADRs only occur in some patients, and (c) develop better tests to identify these ADRs early before the reactions develop or become more severe. Another important effect of creating the Centre will be to increase scientific expertise in this area which is important for our healthcare system, regulatory agencies and pharmaceutical industry.

Technical Summary

We propose to create a Centre for Drug Safety Science at the University of Liverpool, in collaboration with the University of Manchester, the MRC Toxicology Unit in Leicester, the Medicines for Healthcare products Regulatory Agency (MHRA) and Pharmaceutical Industry. This will provide a centre of excellence for research into drug safety, which is important because: (a) adverse reactions to drugs are common accounting for hospitalisations, visits to GPs and in some cases, patient deaths; (b) drugs continue to be withdrawn from the market because of safety concerns with adverse economic consequences and reduced expenditure on future R & D; (c) the number of new drugs coming onto the market has been poor over the last decade; and (d) the combination of drug withdrawals and lack of new drugs will adversely affect drug choice for patients.

Our mission in the Centre will be to enhance drug safety by developing a facility that will enable research that goes from the laboratory bench to the patient bedside (and vice versa) to identify, evaluate and understand the fundamental mechanisms of adverse drug reactions. We have a 20-year track record of research in this area. The Centre will allow us to consolidate and strengthen this expertise, and will have an unrivalled breadth of research ranging from fundamental cellular processes through animal physiology and pathology to modelling and human population studies, inter-linked in a real sense to add value to research into drug safety science right through from molecule to man. We believe that with Centre status we will be able to compete at the highest levels internationally in undertaking translational research in drug safety for the benefit of patients, the public, the industry and regulators. We have several objectives for the Centre: (a) enhance the safety of medicines; (b) provide new knowledge that informs the design and development of medicines in the future; (c) provide an environment for collaboration between scientists from Academia, NHS, Government and Industry; (d) facilitate training for safety scientists from both clinical and basic backgrounds; and (e) provide impartial advice to all relevant stakeholders.

Most importantly, we believe that a fundamental understanding of the mechanisms of adverse drug reactions will serve to inform the patient, the doctor and the medicinal chemist about the risk-benefit of new medicines and through this make drug therapy safer. This is the ultimate aim of our proposed Centre for Drug Safety Science.

Publications

10 25 50

publication icon
Adebayo D (2012) Mechanistic biomarkers in acute liver injury: are we there yet? in Journal of hepatology

publication icon
Alzahrani A (2017) Dapsone and Nitroso Dapsone Activation of Nai¨ve T-Cells from Healthy Donors. in Chemical research in toxicology

publication icon
Antoine DJ (2009) High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. in Toxicological sciences : an official journal of the Society of Toxicology

 
Description Member of SCAHT Scientific Advisory Board
Geographic Reach Asia 
Policy Influence Type Participation in advisory committee
 
Description Personalised Medicine high level group- Round table discussion 17th November Sir Bruce Keogh
Geographic Reach National 
Policy Influence Type Implementation circular/rapid advice/letter to e.g. Ministry of Health
 
Description Re-appointment to Commision on Human Medicines
Geographic Reach National 
Policy Influence Type Participation in advisory committee
 
Description Re-appointment to Commission on Human Medicines for Professor Park
Geographic Reach National 
Policy Influence Type Participation in advisory committee
 
Description BBSRC CASE award with AstraZeneca
Amount £107,000 (GBP)
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 10/2010 
End 09/2014
 
Description BBSRC CASE award with GSK
Amount £148,000 (GBP)
Organisation GlaxoSmithKline (GSK) 
Sector Private
Country Global
Start 10/2009 
End 09/2013
 
Description Clinical Pharmacology Training Scheme
Amount £3,012,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2010 
End 08/2017
 
Description European Commission FP7
Amount € 393,062 (EUR)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 10/2013 
End 09/2018
 
Description MRC Case award with AstraZeneca - 2012
Amount £86,104 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2012 
End 09/2016
 
Description MRC ITTP Studentship - 2009
Amount £80,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2009 
End 09/2013
 
Description MRC ITTP Studentship - 2009
Amount £80,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2009 
End 09/2013
 
Description MRC ITTP Studentship - 2010
Amount £82,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2010 
End 09/2014
 
Description MRC ITTP Studentship - 2010
Amount £82,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2010 
End 09/2014
 
Description MRC ITTP Studentship - 2011
Amount £80,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2011 
End 09/2015
 
Description MRC ITTP Studentship -2010
Amount £82,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2010 
End 09/2014
 
Description MRC ITTP studentship - 2013
Amount £83,712 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2013 
End 09/2017
 
Description NIHR Project grant
Amount £263,394 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start  
 
Description NWCR Project grant - Neil Kitteringham
Amount £111,147 (GBP)
Organisation North West Cancer Research (NWCR) 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2014 
End 02/2016
 
Description North West Cancer Research project grant
Amount £111,147 (GBP)
Funding ID CR986 
Organisation North West Cancer Research (NWCR) 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2014 
End 12/2015
 
Description PRIOMEDCHILD PAMPER consortium
Amount £179,237 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2011 
End 12/2014
 
Description RCUK China Office Travel Grant
Amount £13,000 (GBP)
Organisation Research Councils UK (RCUK) 
Sector Public
Country United Kingdom
Start 06/2010 
End 07/2010
 
Description SC4SM Phase II Project Grant
Amount £623,743 (GBP)
Organisation Stem Cells for Safer Medicines (SC4SM) 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2011 
End 05/2014
 
Description SENSIT-IV Project grant
Amount £1,209,270 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start  
 
Description Travelling Fellowship
Amount £3,000 (GBP)
Organisation The Royal Society 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2010 
End 12/2010
 
Description UK Regenerative Medicine Platform
Amount £4,586,388 (GBP)
Funding ID MR/K026739/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2013 
End 08/2017
 
Description UKRMP Capital Equipment Call
Amount £3,307,918 (GBP)
Funding ID MR/L012707/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 04/2014 
End 03/2015
 
Description Wellcome Trust project grant
Amount £282,171 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2011 
End 05/2015
 
Title Absolute quantification of protein 
Description Method for the absolute quanitification of proteins using stable isotope labels. 
Type Of Material Technology assay or reagent 
Year Produced 2006 
Provided To Others? Yes  
Impact We have continued to develop and exploit this type of approach for the analysis of cancer progression, metastasis and drug toxicity. 
 
Title Blood samples from IFNbeta treated MS patients 
Description Periperal blood mononuclear cells from multiple sclerosis patients treated with IFNbeta to allow us to assess the potential role of T regulatory cells in the generation of binding and neutralising antibodies 
Type Of Material Database/Collection of Data/Biological Samples 
Provided To Others? No  
Impact Pilot data has been used for a project grant application 
 
Title Healthy Volunteer HLA-typed Biobank 
Description A HLA-typed biobank of peripheral blood mononuclear cells for 400 healthy volunteers to a allow for a better mechanistic understanding of drug-induced hypersensitivity reactions 
Type Of Material Database/Collection of Data/Biological Samples 
Year Produced 2010 
Provided To Others? Yes  
Impact Defining a new paradigm for analysing the impact of the immune system on drug-induced organ injury 
 
Description AstraZeneca Project Grant 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Evaluation of the role of acyl glucuronides in liver toxicity
Collaborator Contribution Provision of specifically synthesised chemicals for research project
Impact Funding for 1 postdoctoral fellow
Start Year 2009
 
Description AstraZeneca donation 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution development of clinical study to biobank blood samples from 400 healthy human volunteers
Impact Biobank of HLA-typed healthy volunteer blood cells (described under Research Materials, G0700654B)
Start Year 2009
 
Description AstraZeneca project grant 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Mechanistic investigation of ximelagatran-induced liver injury
Collaborator Contribution Access to equipment Provision of drug compound Evaluation of specific transgenic model system
Impact Funding for 3 postdoctoral fellows
Start Year 2009
 
Description Donation of a mass spectrometer 
Organisation Merck
Department Institute of Drug Metabolism and Pharmacokinetics
Country Germany 
Sector Private 
PI Contribution Discussions on safety biomarker strategies with Merck scientists that should lead to formal project grant support
Collaborator Contribution Donation of an ABSciex API4000 mass spectrometer
Impact None yet
Start Year 2011
 
Description Donation of a mass spectrometer 
Organisation Pfizer Ltd
Country United Kingdom 
Sector Private 
PI Contribution Discussions on drug safety science strategies with individual Pfizer scientists and through CDSS workshops
Collaborator Contribution Donation of an ABSciex API4000 QTRAP mass spectromenter
Impact Significantly enhanced analytical capacity in CDSS that will help to support the substantial IMI-funded MIP-DILI project
Start Year 2013
 
Description Drug toxicity / Andrew Stachulski 
Organisation University of Bath
Department Department of Chemistry
Country United Kingdom 
Sector Academic/University 
PI Contribution Ongoing long term collaboration to elucidate mechanisms of drug toxicity. We have provided expertise in protein mass spectrometry to complement their expertise in low molecular weight mass spectrometry.
Collaborator Contribution Chemical expertise has made significant contributions to our understanding of protein biochemistry in adverse drug reactions. They have also been involved in synthesising reagents for protein quantification.
Impact PMID: 17985860
 
Description GSK studentship 2013 
Organisation GlaxoSmithKline (GSK)
Department Research and Development GSK
Country United Kingdom 
Sector Private 
PI Contribution Scientific lead for project Supervision of student
Collaborator Contribution Financial support Placement of student at GSK research labs for at least 3 months of project
Impact None
Start Year 2013
 
Description Hartmut Jaeschke 
Organisation Research Medical Center, Kansas
Country United States 
Sector Hospitals 
PI Contribution Characterisation and quantitation of emerging and novel biomarkers of drug-induced liver injury
Collaborator Contribution Collaboration to investigate mecahnisms of paracetamol-induced liver damage through the provision of patient samples.
Impact One paper published (PMID 21396389) and another under revision.
Start Year 2010
 
Description Leeds Cystic Fibrosis Unit 
Organisation St James's University Hospital (Jimmy's)
Department Cystic Fibrosis Centre
Country United Kingdom 
Sector Hospitals 
PI Contribution Bioanalysis of blood samples
Collaborator Contribution Access to patient blood samples to further our mechanistic research into beta-lactam hypersensitivity
Impact Publication -PMID 20481640
Start Year 2009
 
Description MMV research grant 
Organisation Medicines for Malaria Venture (MMV)
Country Switzerland 
Sector Charity/Non Profit 
PI Contribution Scientific lead on project Training and management of postdoctoral fellow
Collaborator Contribution Financial Scientific input into direction of project through monthly teleconferences
Impact None yet
Start Year 2012
 
Description MMV research project - primaquine 
Organisation Medicines for Malaria Venture (MMV)
Country Switzerland 
Sector Charity/Non Profit 
PI Contribution Scientific leadership and research activities from two postdoctoral fellows
Collaborator Contribution Scientific input into project Progress evaluation through monthly teleconferences
Impact None yet
Start Year 2014
 
Description Mass Spectrometry Interactions 
Organisation Life Technologies
Department Applied Biosystems
Country United States 
Sector Private 
PI Contribution Feedback on technical issues with mass spectrometry equipment. Guidance as to the future direction of software development.
Collaborator Contribution Technical expertise in advanced mass spectrometry and associated software.
Impact 19041286 16479536 Also produced technical notes on quantitation of proteins
 
Description Novartis collaboration 
Organisation Novartis Institutes for BioMedical Research (NIBR)
Country United States 
Sector Private 
PI Contribution Discussions on potential mechanisms of lumiracoxib toxicity
Collaborator Contribution Provision of lumiracoxib
Impact None yet but in late stage negotiation for a formal project grant agreement
Start Year 2012
 
Description SAFE-T consortium formal collaborator 
Organisation European Commission
Department Innovative Medicines Initiative (IMI)
Country Belgium 
Sector Public 
PI Contribution Intellectual leadership Provision of novel biomarker techniques for potential use in clinical setting Provision of clinical samples
Collaborator Contribution Progressing a number of biomarkers and assays that we have identified for formal validation and qualification for potential use in clinical studies
Impact The collaboration has strengthened our links with Industry and has placed us in a good position to lead a bid for the 3rd Call IMI topic on drug induced liver injury
Start Year 2010
 
Description Scottish Poisons Information Bureau 
Organisation Scottish Poisons Information Bureau
Country United Kingdom 
Sector Public 
PI Contribution Evaluation of emerging and novel biomarkers of drug-induced liver (and kidney) injury
Collaborator Contribution Provision of blood and urine samples from paracetamol overdose patients exhibiting liver damage
Impact Puiblication evaluating miR122 as a potential sensitive and specific biomarker of liver damage, PMID: 22045675. Recently reviewed in Faculty of 1000. Additional high -impact publications in development.
Start Year 2010
 
Description sanofi aventis project grant 
Organisation Sanofi
Department Aventis
Country France 
Sector Private 
PI Contribution Evaluation of mechanisms of toxicity associated with existing and follow-on drugs
Collaborator Contribution Secondment of sanofi-aventis postdoctoral fellow to the CDSS for 3 months at start of project to facilitate expertise exchange
Impact Enhancing profile of CDSS within Industry. No publications to date.
Start Year 2011
 
Title METHOD FOR THE DETECTION OF ORGAN OR TISSUE INJURY 
Description This invention relates to methodology for detecting, assessing and/or diagnosing the presence of organ or tissue injury using blood-borne biomarkers CK18 and HMGB1 
IP Reference CA2766739 
Protection Patent application published
Year Protection Granted 2010
Licensed No
Impact Significant publications on the value of using these markers for predicting/detecting DILI in patients
 
Title Method for the detection of organ or tissue injury 
Description Methodology for detecting serum biomarkers that can be used in the detection, assessment and/or diagnosis of drug induced organ or tissue injury. The biomarkers comprise one or more of caspase-cleaved keratin 18, full-length keratin 18, hypo-acetylated HMGB1 and acetylated HMGB1. 
IP Reference US8748109 
Protection Patent granted
Year Protection Granted 2014
Licensed No
Impact Other patents granted: European patent number EP2449378; Japanese patent number 5721707
 
Description Academy of Medical Sciences/Wellcome Trust meeting on 'Evaluating evidence in health', October 2015 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The workshop 1-day meeting for approximately 50 delegates, who will be senior representatives from academia, industry, the regulatory sector and the wider healthcare landscape. The workshop designed for discssion with the aim of • Examine the strengths and limitations of evidence from different sources for determining risks (adverse events) and benefits (efficacy and effectiveness) of medicinal products.
• Explore how weaknesses in current approaches might be addressed, including discussion around evolving and novel trial designs, and methods of data collection, analysis and meta-analysis.
• Consider the future sources of data and how they might be used as evidence.
• Discuss how evidence can be effectively communicated to stakeholders, including patients, citizens, healthcare professionals and the media.
• Generate practical suggestions for enabling the better use of research evidence in healthcare decisions.

The outputs from this workshop will feed into the Academy's working group project on 'Methods of evaluating evidence' and work informing the Wellcome Trust's approach for accelerating the uptake of research into policy and practice.
Year(s) Of Engagement Activity 2015
 
Description 12th November 2015 - AHSN/ NHS ENGLAND EVENT LIVERPOOL 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact opportunity to shape personalised medicine in the NHS

NHS England Held three regional events with the Academic Health Science Networks (AHSNs) for representatives across their geographies to support the development of a strategy for a personalised medicine service for the NHS. The vision is that the strategy will embrace four overarching principles: prediction and prevention of disease; more precise diagnoses; targeted and personalised interventions; and a more participatory role for patients. this was achieved at the event with future plans made to implement the strategy
Year(s) Of Engagement Activity 2015
 
Description 2015 MISG New Technologies Forum on umbrella and basket protocols 27th October 2015.2FB. 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Type Of Presentation keynote/invited speaker
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact 2015 MISG New Technologies Forum on umbrella and basket protocols

raise awareness and understanding suppor best practice and produce recommendations for future regulatory guidance

assisted with the thinking in the proposals put forward
Year(s) Of Engagement Activity 2015
 
Description ASCPT 2015 March 2015 New Orleans 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Type Of Presentation keynote/invited speaker
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact GREATER UNDERSTANDING OF PERSONALIZED MEDICINE USING GENOMEWIDE APPROACHES

INVITATION TO DISCUSS AT FUTURE EVENTS
Year(s) Of Engagement Activity 2015
 
Description Academic Health Science Networks - Medicines Optimisation Event 26th November 2015 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The day is to bring together AHSN teams working on MO to share progress on projects, to solve problems together and to build knowledge; in addition, the day will allow exchange of information with NHS E, ABPI and RPS. Through this we seek to build momentum for change, improve quality of each programme and ensure spread of improvement. There will be breakout sessions including one for those with Patient Safety Collaborative workstreams on medicines.

Safety - including thinking around the collaboratives
Outcomes - including implementing NICE TAs, building a case for use 'value based healthcare'
Patient Experience - including adherence
Year(s) Of Engagement Activity 2015
 
Description British Pharmaceutical Students' Association (BPSA), EASTERN CONFERENCE LINCOLN 7th NOVEMBER 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Postgraduate students
Results and Impact Eastern Area Coordinator for the a student organisation representing over 14,500 pharmacy students across England and Wales.

presentation delivered on topic of Personalised Medicine, encompassing two strands: pharmacogenetics (drug and dose selection based on individual genetic profiling) and personalising care through practice.


The conference will host students from all four years of the MPharm course and from a range of different universities. We welcome a variety of methods of presenting the content to students and normal lecture room facilities are in place for you to present your topic.
Each conference normally attracts around 200 delegates at each conference. This is a fantastic opportunity for students to learn new skills and to gain knowledge related to the material that they may not encounter in depth at university. As the future of the pharmacy profession, it is vital for students to develop such knowledge in order to shape their careers.


Sahred with students what pharmacists of tomorrow need to know in regards to this topic.
Year(s) Of Engagement Activity 2015
 
Description CDSS Worskshop Gi toxicity December 1st 2015 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Talk sparked discussion regarding governance /reporting of GI Toxicity

further information requested
Year(s) Of Engagement Activity 2015
 
Description CPD lecture for MHRA speech the role of pharmacogenetics in drug safety 30th September 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Health professionals
Results and Impact the lectures are organised for MHRA assessor staff and are broadly based on the syllabus for physicians undertaking specialist training in pharmaceutical medicine.
The audience usually comprises a range of medical, pharmaceutical/quality, non-clinical, scientific and statistical assessors.


role of pharmacogenetics in drug safety presentation generated discussion and stimulation of ideas.
Year(s) Of Engagement Activity 2015
 
Description Cheshire WI presentations 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact 150 members of the Cheshire WIheard about the work of the CDSS in general and stem cell research in particular

None
Year(s) Of Engagement Activity 2011
 
Description Chief Scientific Officer Conference 1st March 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact The Vision For 2020 is aimed at senior leaders and healthcare scientists at all levels to start encouraging them to look to the future. healthcare scientists across all disciplines attended the event with the aim to show the depth and breadth of expertise that there is the event covered key changes and challenges in the healthcare and healthcare science landscape,
1. Science at the heart of the constitution
2. Healthcare Scientists delivering the change
3. Emerging science
4. Building the capacity and capability for change
my contribution was bringing my expertise and knowledge to the theme of Personalised medicine
Year(s) Of Engagement Activity 2016
 
Description DSRU's 8th Biennial Signal Detection Conference June 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation keynote/invited speaker
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact TO ENGAGE WITH Pharmaceutical companies from Europe uk USA to discuss progress in The pharmacogenetic basis of adverse drug reactions

improved knowledge
Year(s) Of Engagement Activity 2015
 
Description FOCUS 2015, the National Meeting of the Association for Clinical Biochemistry and Laboratory Medicine,9-11th June 2015 in Cardiff 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation keynote/invited speaker
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact To assist thinking and understanding to medical and clinical scientist consultants in clinical biochemistry and trainees at various stages to . purpose of this symposium is to update on scientific principles and to highlight any areas likely to be of particular relevance to the hospital diagnostic laboratory.

Improved learning and knowledge from audience
Year(s) Of Engagement Activity 2015
 
Description Farr Institute International Conference 2015, St Andrews, 26 - 28 August 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation keynote/invited speaker
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact share thinking on the linkage with record darta and health informatics

researchers/ policy makers keen n the subject matter of topic of Linking Phenotype and Genotype
Year(s) Of Engagement Activity 2015
 
Description IFCE CONFERENCE PARIS jUNE 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation keynote/invited speaker
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact New Developments in Pharmacogenetics" SPEECH to stimulate thinking

Stimualted thnking amongst those present
Year(s) Of Engagement Activity 2015
 
Description ISSX Glasgow June 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation keynote/invited speaker
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact presentation on Implementation of Pharmacogenomics in Clinical Practice-focus on evidence-based medicine and cost-effectiveness".

Greater understanding on th need for cost effectiveness for the need of Pharmacogenomics in Clinical Practice
Year(s) Of Engagement Activity 2015
 
Description JOINT BTS/BPS Joint Meeting, OCTOBER 2015 -EDINBURGH 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation keynote/invited speaker
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact SPEECH DELIVERED : Drug safety pharmacogenomics :breaktrhoughs, challenges and opportunities -
challenged thinking and new ways of working

additional requests / enquiries made in relation to CPT
Year(s) Of Engagement Activity 2015
 
Description Joint ASCEPT-BPS Scientific Meeting May 2015 hong kong 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation paper presentation
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact symposium Phenotyping vs genotyping in HK slot of presentation
presentation delivered " Has genotyping fulfilled its hopes to individualise drug therapy" and chared a session on Drug Discovery, Development And Evaluation

debate stimluated on the presentation delivered " Has genotyping fulfilled its hopes to individualise drug therapy" outlined next steps in this areas
Year(s) Of Engagement Activity 2015
URL http://ascept-bps2015.com/programme-and-keynote-speakers-2/
 
Description Kuala Lumpar - Next generation pharmacogenomics March 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation keynote/invited speaker
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact debate generated personalised medicine the challenging of developing the evidence base

students, academics and health professionals debated about such issues to inform discussion
Year(s) Of Engagement Activity 2015
 
Description LHP / NICE CONFERENCE liverpool 14.10.2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation keynote/invited speaker
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact dsicussion centred on How genetics can impact healthcare
- Increased availability of genetic testing and the future of primary care
- The importance of a free NHS in the era of genetic medicine
- Opportunities for personalised medicine


Increased knowledge and appetitle for Personalised medicine
Year(s) Of Engagement Activity 2015
 
Description Lecture - university of Leeds 9th December 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact lecture Stratified Medicine in 2015 - challenges and opportunities" provided students with opportunity to here the latest innovations in stratified medicine and challenge new ideas

a request for further lectures was made feedback generated much interest
Year(s) Of Engagement Activity 2015
 
Description Local PROBUS presentation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Presentation to 60 members of the Runcorn PROBUS group on the work of the CDSS

None
Year(s) Of Engagement Activity 2011
 
Description MRC Biannual Directors' Meeting. 18th November 2015 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Information giving wIth colleagues associated with MRC

Continued discussion and dialogue on areas of research that affect/ impact and progress research initiatives
Year(s) Of Engagement Activity 2015
 
Description MRC Centenary open day 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact An open evening to highlight MRC-funded reserach at the University of Liverpool. Highlights included the showing of a film about the Centre for Drug Safety Science and a keynote lecture from Lawrence McGinty

Local radio interview
Year(s) Of Engagement Activity 2013
 
Description Making Sense of Drug Safety Science 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Creation of a public awareness booklet called "Making Sense of Drug Safety Science" in collaboration with Sense About Science

Too early to say
Year(s) Of Engagement Activity 2013
URL http://www.senseaboutscience.org/resources.php/138/making-sense-of-drug-safety-science
 
Description Medicine in 1925 and in 2015: a symposium to mark the 90th Anniversary of the Postgraduate Medical Journal 1st october 2015 London 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation keynote/invited speaker
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact presentation Progress in Personalised Medicines stimulated debate in the advancements of medicine from 1925 to present day.

request for further information in respect of topics covered in speech
Year(s) Of Engagement Activity 2015
 
Description NCRI CANCER CONFERENCE Liverpool 3rd November 2015 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact SYMPOSIUM "How integration of germline genetic information can improve diagnosis, treatment and prevention of cancer "


REQUESTS MADE FOR FURTHER INFORMATION ON THE TOPIC AREA
Year(s) Of Engagement Activity 2015
 
Description NIHR CRN National Coordinating Centre - Visit from Jonathan Sheffield and Team to Alder Hey 7th January 2016 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Members of NIHR / CRN met with the Trust board and University to discuss strategic priorities and future plans in the area of Stratified/Personalised Medicine


greater awareness and understanding of the theme of stratified and personalised medicine
Year(s) Of Engagement Activity 2015
 
Description NIHR SENIOR investigator MEETING 3-4th November 2015 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact DISCUSSION ABOUT KEY ISSUES FACING NIHR AND ITS FUTURE DEVELOPMENT AND STRATEGY
Year(s) Of Engagement Activity 2015
 
Description NWAC - ALCHOHOL CONFERENCE Liverpool 20th November 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Health professionals
Results and Impact Free conference to all medical, nursing, AHP, social care and third sector delegates, including students in relevant disciplines.

Discussions is again free to all medical, nursing, AHP, social care and third sector delegates, including students in relevant disciplines.

Discussions on the international, national and local perspectives will be supplemented by the showcasing of good practice examples and shared learning from practitioners across the country.

NWAC15 provided an unparalleled learning opportunity to exchange thoughts with peers, and build awareness of the range of approaches taken to reduce the harm caused to individuals and communities by alcohol abuse.





Participant advised that they left with insight which improved their own practice for patients and service users, as well as greater knowledge on how the national agenda is shaping up.
Year(s) Of Engagement Activity 2015
 
Description PHARMACOLOGY 2015 LONDON 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation workshop facilitator
Geographic Reach National
Primary Audience Industry/Business
Results and Impact Generated discussion regarding CPT in NHS and the whole area of Pharmacology within UK
Year(s) Of Engagement Activity 2015
 
Description PHARMARELA8 CONFERENCE February 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact debate on Genomics and therapeutics generated discussion on future direction of genomics and into impact in therapeutics
Year(s) Of Engagement Activity 2016
 
Description POLANI LECTURE February 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact POLANI LECTURE at Guys hospital makeup of the audience was geneticists, bioinformaticians, immunologists, dermatologists, clinicians, research workers (ranging from heads of groups to research students), and other interested parties.

confirmed title Precision Medicine and Drug Safety: Opportunities and Challenges" followed by informal chat with Students
Year(s) Of Engagement Activity 2016
 
Description PSMN WORKSHOP LONDON NOVEMBER 11TH 2015 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Work shop identified and highlighted progress and innovation in the filed of stratified medicine.

Ability to learn from industry and other collaborative partners on future direction of stratified medicine
Year(s) Of Engagement Activity 2015
 
Description Parliamentary Reception 14th december 2015 - BPS 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact To discuss and promote CPT guidance in NHS

further request for attendance at NHS England meetings and with chief medial officers in Scotland, Ireland and Wales
Year(s) Of Engagement Activity 2015
 
Description Personalised Medicine Conference in Oxford April 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The conference is jointly organised by the Centre for Personalised Medicine in Oxford (a collaboration between the Wellcome Trust Centre for Human Genetics in Oxford and St Anne's College) and the PMWC

A series of these conferences, organised by PMWC, have been held very successfully every year in Stanford. The Oxford conference will be the first of this series in Europe. 300 people, drawn from industry, academia, and the healthcare sector, to gather in Oxford across the three days for a conference focused on where personalised medicine fits in the clinic and on the practical applications of personalised medicine both now and in the near future.





insights and expertise in my role as NHS Chair of Pharmacogenetics provided a valuable addition to the conference
Year(s) Of Engagement Activity 2015
 
Description RCP ANNUAL CONFERENCE JUNE 2018 500TH ANNIVERSARY 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Royal College of Physicians runs a flagship annual conference for its fellows, members and other stakeholders from healthcare for secondary care doctors in the UK. The 2018 event - Innovation in Medicine 2018: and will mark the 500th anniversary of the founding of the College by King Henry VIII. key celebratory event that year and we will use it to celebrate the past achievements of the RCP and wider medicine, as well as look forward to the innovations of the future.
Year(s) Of Engagement Activity 2018
 
Description RCP advanced medicine conference Feb 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact talked on the topic of 'Important drug interactions' and chaired the session on pharmacology
The event is a long-running and integral part of the annual RCP conferences programme t is designed to provide advanced medicine training to all physicians and to cover latest cutting-edge advances in clinical practice, underpinned by an improved understanding of the disease mechanism. The conference is one of the RCP's most high-level academic programmes and it's important to present the most cutting-edge scientific advances from across the specialties.
Year(s) Of Engagement Activity 2016
 
Description Risk in Medicine Personalized Health / Risk Workshop 2.10.2017 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact The Liverpool Institute for Risk and Uncertainty and the Wolfson Centre for Personalised Medicine held an informal convocation - The workshop included select informal talks from researchers in both risk science and personalized medicine, poster presentations about existing projects and ideas, and general open discussion about possible interactions between risk and medical researchers
Year(s) Of Engagement Activity 2017
 
Description STRATEGY RETREAT & BPS COUNCIL MEETING June 2015 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact strategy going forward discussed

strategy for BPS AGREED
Year(s) Of Engagement Activity 2015
 
Description Sense About Science topic specialist 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Providing scientifically correct statements for journalists on topics associated with drug safety and drug toxicity

Better links with Sense About Science
Year(s) Of Engagement Activity 2009,2010
 
Description Trip to McLaren Woking 30th October 2015 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Participants in your research and patient groups
Results and Impact Trip to McLaren in Woking was to tease out potential collaboration and information in respect of public engagement and participation in activities to improve public Health,



potential collaboration and sharing of ideas for developing initiatives was explored.
Year(s) Of Engagement Activity 2015
 
Description U-PGx Kick-off meeting Leiden Jan 2016 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Kick off Meeting for developing Systems pharmacology and Drug-drug interactions as part of a European consortium with other research institutes with a focus on ICT tools and the PGx infrastructure
Year(s) Of Engagement Activity 2016
 
Description UKCCRF Manchester June 26th 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Precision medicine in the ICU: The role of pharmacogenomics
Year(s) Of Engagement Activity 2015
 
Description Voice of Young Science Forum 2010 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Approx 60 Degree and PhD students took part in forum on Science and the Media

Entered into a collaboration with Sense About Science to develop a "Making Sense of Drug Safety Science" pamphlet
Year(s) Of Engagement Activity 2010
 
Description Welsh Sixth Form Conference 2014 'Discovering Genomics' (Dan Hawcutt and Vincent Yip) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact A presentation delivered to sixth form students entitled 'Pharmacogenomics: Personalising Medicine' was delivered to an audience of Sixth From students and the Wales Gene Park sixth form conference. The presentation sparked questions and discussion from the students.

Further invitations to take part in this kind of event.
Year(s) Of Engagement Activity 2014
URL http://www.walesgenepark.cardiff.ac.uk/2014/10/15/sixth-form-conferences-2014/
 
Description Wilton Park dialogue 'The impact of the genomics revolution on global health - how can governments respond - March 2016 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Invitation to attend a high-level Wilton Park dialogue organised in partnership with the Foreign and Commonwealth Office, the Science and Innovation Network (SIN) and Healthcare UK. The meeting focused on the potential of genomics and new precision medicines, including discussion on how governments can respond.
Year(s) Of Engagement Activity 2016